Immune Dysfunction in Allergic Asthma

This study has been completed.

First Received: September 10, 2005 Last Updated: January 30, 2009 History of Changes

Sponsors and Collaborators:	University of New Mexico National Heart, Lung, and Blood Institute (NHLBI)
Information provided by:	University of New Mexico
ClinicalTrials.gov Identifier:	NCT00189228

Purpose

We are using anti-IgE to investigate the role of pulmonary mast cells in asthma.

Condition	Intervention
Asthma	Drug: anti-IgE Drug: Xolair

MedlinePlus related topics: Asthma

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Diagnostic, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study
Official Title:	Not a Drug Trial. We Are Using Anti-IgE to Examine the Role of Pulmonary Mast Cells in Asthma

Further study details as provided by University of New Mexico:

Estimated Enrollment:	18
Study Start Date:	September 2005
Study Completion Date:	June 2008
Primary Completion Date:	June 2008 (Final data collection date for primary outcome measure)

Detailed Description:

Subjects with mild allergic asthma are examined before, immediately after and 2 months after a course of treatment with anti-IgE. The following are examined: Allergen skin tests, allergen induced asthma, peripheral blood basophils, pulmonary bronchial mucosal mast cells.

Eligibility

Ages Eligible for Study:	18 Years to 45 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Mild asthma, adults -

Exclusion Criteria:

children. on inhaled or systemic steroids

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00189228

Locations

United States, New Mexico
UNM HSC
Albuquerque, New Mexico, United States, 87131

Sponsors and Collaborators

University of New Mexico

National Heart, Lung, and Blood Institute (NHLBI)

Investigators

Study Director:

Mark Schuyler, MD

UNM HSC

More Information

No publications provided

Responsible Party:	UNM ( Mark Schuyler )
Study ID Numbers:	UNMSCOR, NHLBI P50-HL44253
Study First Received:	September 10, 2005
Last Updated:	January 30, 2009
ClinicalTrials.gov Identifier:	NCT00189228 History of Changes
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Hypersensitivity
Lung Diseases, Obstructive
Respiratory Tract Diseases
Bronchial Diseases
Lung Diseases

Hypersensitivity, Immediate
Asthma
Omalizumab
Respiratory Hypersensitivity

Additional relevant MeSH terms:

Hypersensitivity
Lung Diseases, Obstructive
Immune System Diseases
Respiratory Tract Diseases
Bronchial Diseases

Lung Diseases
Hypersensitivity, Immediate
Asthma
Respiratory Hypersensitivity

ClinicalTrials.gov processed this record on May 07, 2009